Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 6Octreotide literaturebiorxiv-preprint · Review2026

Carcinoid Heart Disease: Surgical Timing, Right Ventricular Risk Stratification and Operative Strategy

Operative mortality for carcinoid heart disease is now 5–6% in high-volume centers, and continuous octreotide infusion can reduce carcinoid crisis incidence.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the octreotide corpus
0
Preclinical
5
Observational
0
Open-label
0
Randomised
1
Reviews · this one

Summary and findings

This review addresses carcinoid heart disease, focusing on surgical timing and right ventricular risk stratification. It reports that operative mortality has decreased to 5–6% in high-volume centers and emphasizes the importance of preoperative right ventricular function. Continuous perioperative octreotide infusion is noted to have reduced the incidence of carcinoid crisis.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
5–6% operative mortality in contemporary high-volume centres.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Carcinoid heart disease is a progressive right-sided valvulopathy caused by serotonin and other vasoactive mediators released by metastatic neuroendocrine tumours. As oncological therapies have extended survival, cardiac disease has become a leading determinant of mortality. Operative mortality has decreased to 5–6% in contemporary high-volume centres, and long-term survival appears increasingly determined by tumour biology rather than cardiac disease when surgery is appropriately timed. The principal determinant of operative outcome is preoperative right ventricular function; symptom-based referral alone is insufficient because many patients remain compensated until ventricular dysfunction is advanced. This review synthesises the evidence on surgical timing, operative strategy, prosthesis selection, perioperative endocrine management, and emerging transcatheter options. Tricuspid valve replacement is required in the majority of patients, with concomitant pulmonary valve replacement advocated where concurrent disease is present. Bioprosthetic valves are preferred. Continuous perioperative octreotide infusion has substantially reduced the incidence of carcinoid crisis. Structured multidisciplinary decision-making integrating echocardiographic surveillance, biomarker monitoring, and oncological status assessment is essential.

Elsewhere in the Octreotide corpus

BEx Vivo Drug Sensitivity in Patient-derived 3D Cultures in Acromegaly and its Association with Clinical Predictorsbiorxiv-preprint · 2026 · Median cell viability reduction of 84-86%, p < 0.05.HumanBManagement of Chylous Acid in Gynecological Malignanciesbiorxiv-preprint · 2026 · 830 mL on POD 4 serves as a significant clinical predictor for standardizing the timing of advanced conservative intervention.HumanBSurgical management and risk factors of chylothorax following congenital heart surgerybiorxiv-preprint · 2026 · Chylothorax resolved in 53 patients (82.8%) through conservative management, n=64.HumanBElimination Capacity Determines Outcome in Amatoxin Mushroom Poisoning-Induced Acute Liver Failure: A Globally Applicable Management Frameworkbiorxiv-preprint · 2026 · Transplant-free recovery: 98.8% among protocol-adherent patients (n=86).HumanBAcute Promyelocytic Leukaemia Presenting as Bleeding in a Minor Burn Patient: A Case Reportbiorxiv-preprint · 2026 · Not reported in abstract.Human